Scientific Reports (Sep 2022)

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia

  • Cheng Siang Tan,
  • Vaenessa Noni,
  • Whilemena Upam Herman Ulok Melina,
  • Ummi Syafiqah Abdorahman,
  • Joseph Niler Bimbang,
  • Natasya Marliana Abdul Malik,
  • Mohammad Esa Hossen,
  • Md Mizanur Rahman,
  • Lela Su’ut,
  • Asri Said,
  • Claire Chen,
  • Bego Sepop,
  • Morni Abu Samat,
  • John Chee Ming Chew,
  • Dewi Mamora,
  • Sian Kong Tan

DOI
https://doi.org/10.1038/s41598-022-19776-3
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Several vaccines have been fast-tracked through clinical trials to mitigate the progression of the SARS‑CoV‑2 pandemic. We analyzed sequential blood samples from 314 recipients of Comirnaty and CoronaVac in East Malaysia for the spike-binding IgG (IgG-S), nucleocapsid-binding IgG (IgG-N), spike-binding IgM (IgM-S) and serum vitamin D (VitD). A subset of samples was analyzed for the neutralizing antibodies (Ig-RBD). Results showed that IgG-S due to Comirnaty was significantly higher than CoronaVac. IgM-S was detected in 80.0% Comirnaty and 69.5% CoronaVac recipients, while IgG-N was detected in 58.1% CoronaVac but not in Comirnaty recipients. All IgG-S-positive vaccines possessed detectable Ig-RBD after the second dose but with a weak to moderate correlation. The serum VitD levels did not influence the antibody magnitude in both vaccines. In essence, SARS-CoV-2 vaccination is an IgG-S-dominant event, Comirnaty was more effective than CoronaVac in mounting IgG-S and Ig-RBD responses, independent of the patient’s VitD level.